Publication related to RSI or an RSI staff member
Derivation of whole blood biomonitoring equivalents for titanium for the interpretation of biomonitoring data.
Biomonitoring equivalents (BEs) have been increasingly applied for biomonitoring purposes by regulatory bodies worldwide. The present report describes the development of a BE for titanium based on a 4-step process: (i) identification of a critical study/point of departure (PoD) supporting an established oral exposure guidance value (OEGV);, (ii) review the available oral PK data and application of a pharmacokinetic model for titanium; (iii) selection of the most appropriate biomarker of exposure in a specific tissue and calculation of steady-state tissue levels corresponding to the PoD in the critical study; and (iv) derivation of BE value adjusting for the uncertainties considered in the original OEGV assessment. Using the above 4-step approach, a blood BE value of 32.5 mug titanium/L was derived. Key components of the analysis included a pharmacokinetic model developed by investigators at the Netherlands National Institute of Public Health (RIVM) and a two-year rodent bioassay of titanium conducted by the US National Cancer Institute. The most sensitive pharmacokinetic parameter involved in the current BE derivation is the oral absorption factor of 0.02%. The provisional BE proposed in this article may be updated as new information on the pharmacokinetics of titanium becomes available.
Authors
- Ramoju, S, Ramoju S, Risk Sciences International, Ottawa, ON, Canada. Electronic address: SRamoju@Risksciences.com.
- Andersen, M E, Andersen ME, Risk Sciences International, Ottawa, ON, Canada.
- Nong, A, Nong A, Health Canada, Ottawa, ON, Canada.
- Karyakina, N, Karyakina N, Risk Sciences International, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada.
- Shilnikova, N, Shilnikova N, Risk Sciences International, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada.
- Krishnan, K, Krishnan K, Risk Sciences International, Ottawa, ON, Canada.
- Krewski, D, Krewski D, Risk Sciences International, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada.
Biomonitoring equivalents (BEs) have been increasingly applied for biomonitoring purposes by regulatory bodies worldwide. The present report describes the development of a BE for titanium based on a 4-step process: (i) identification of a critical study/point of departure (PoD) supporting an established oral exposure guidance value (OEGV);, (ii) review the available oral PK data and application of a pharmacokinetic model for titanium; (iii) selection of the most appropriate biomarker of exposure in a specific tissue and calculation of steady-state tissue levels corresponding to the PoD in the critical study; and (iv) derivation of BE value adjusting for the uncertainties considered in the original OEGV assessment. Using the above 4-step approach, a blood BE value of 32.5 mug titanium/L was derived. Key components of the analysis included a pharmacokinetic model developed by investigators at the Netherlands National Institute of Public Health (RIVM) and a two-year rodent bioassay of titanium conducted by the US National Cancer Institute. The most sensitive pharmacokinetic parameter involved in the current BE derivation is the oral absorption factor of 0.02%. The provisional BE proposed in this article may be updated as new information on the pharmacokinetics of titanium becomes available.
